Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lilly Cymbalta gets FDA approval
Cymbalta has been established in studies in patients with chronic low back pain and chronic pain due to osteoarthritis. Cymbalta, which has been shown to reduce chronic low
Cymbalta has been established in studies in patients with chronic low back pain and chronic pain due to osteoarthritis. Cymbalta, which has been shown to reduce chronic low
The biological effects of SoftWave therapy include increased permeability of cell membranes, increased blood flow through angiogenesis, up-regulation of growth factors, and stem cell activation, and also proved
AVP-21D9 is presently in a randomised, double-blind, placebo-controlled, dose escalation Phase I clinical study involving 50 healthy volunteers designed to evaluate the safety and pharmacokinetics of the product
The funding will allow Achillion Pharmaceuticals to further advance its portfolio of HCV clinical candidates, as well as allow it to capitalise certain antibacterial assets. Achillion senior vice
The grants were awarded in recognition of its two qualifying programs: AG-707, a phase 1 therapeutic vaccine for the treatment of genital herpes and QS-21 Stimulon(R) adjuvant. Antigenics
Bromodeoxyuridine (BrdU) – an analog of the DNA base thymidine – is a reagent commonly used in the detection of proliferating cells in living tissues and tissue samples.
DURECT has posted a net loss of $4.65m for the third quarter 2010, or $0.05 loss per diluted share, compared to net loss of $5.54m, or $0.07 loss
To define the potential coverage of 4CMenB against circulating MenB strains, the research investigators examined the characteristics of a collection of 124 MenB strains using pooled sera from
ALN-HTT consists of an RNAi therapeutic targeting huntingtin, the gene responsible for Huntington’s disease, that is being developed for delivery to the central nervous system (CNS) using an
Under the Act, $1bn was earmarked for qualifying therapeutic discovery projects that treat areas of unmet medical need or prevent, detect or treat chronic or acute diseases and